Background: Locally-advanced non-small cell lung cancer (LA-NSCLC) represents a heterogeneous entity, distinct regarding patient-and primary tumor features. Introduction of a simple prognostic score can lead to personalized decision-making in clinical routine. The present study aimed to create a prognostic score for LA-NSCLC patients treated with multimodal therapy. Patients and methods: Data were collated on a total of 100 patients treated with curative-intent multimodal therapy for LA-NSCLC (UICC stage III) . Several prognostic factors including gender, age, ECOG performance status, comorbidity, tobacco consumption, atelectasis before irradiation, COPD, emphysema and histology were analyzed for impact on overall survival (OS). Factors showing a significant negative association with OS on univariate analysis were included and scored with one point. A prognostic score was defined by the following 4 subgroups: low risk (0-1 points), medium risk (2 points), high risk (3 points) and very high risk (4-5 points). Result: Chemoradiotherapy (CRT) was completed by 96 (96%) patients with a total dose range of 50-70Gy. The absolute majority (81%) was treated with a total dose 60Gy. Intensitymodulated radiotherapy (IMRT) was delivered in 40 (40%) cases. 10 (10%) patients were treated with radiotherapy alone, 11 (11%) with sequential and 79 (79%) patients with concurrent CRT. 13 (13%) patients underwent surgery after completion of radiotherapy. Median OS for the entire cohort was 20.8 months (95% CI: 16.229e25.371). Impact on overall survival was found for age (negative in >60 vs. 60 years, p¼0.038), gender (negative in male vs. female, p¼0.016), pack years (PY) (negative in >21 PY vs. 20 PY, p¼0.017), presence of atelectasis before irradiation (negative in yes vs. no, p¼0.019) and tumor histology (negative in squamous cell carcinoma and NOS vs. adenocarcinoma, p¼0.027). Per definition, 11 (11%), 26 (26%), 37 (37%) and 26 (26%) patients were in the low, medium, high and very high risk subgroups, respectively. Median OS was not reached for those with low risk, was 26.4 for medium, 22.0 for high and 13.7 months for patients with very high risk, respectively (p<0.001). Conclusion: The simple prognostic score we developed for patients receiving multimodal treatment for stage III NSCLC may aid physicians in making individual therapeutic decisions and personalizing treatment by defining patients with compromised survival outcomes. Keywords: prognostic score, LA-NSCLC, Chemoradiotherapy (CRT) Background: The common radiation dose for concurrent chemoradiotherapy for patients with stage III non-small cell lung cancer (NSCLC) is 60 Gy, however, we performed carboplatin-paclitaxel chemo radiotherapy with 66 Gy for elderly patients and examined whether that is feasible and effective. Method: One hundred forty-four lung cancer patients underwent radiotherapy in our hospital between 2012 and 2013. In the present study, we analyzed thirty-eight patients with stage III NSCLC out of 144, excluding patients treated with palliative intent in the present study. They were divided into three treatment groups according to age, ECOG performance status (PS) and complications of each patient. Group A patients, who were younger than 70 years old, PS 0 or 1, and without any complications, received the concurrent cisplatin-docetaxel chemoradiotherapy with 60 Gy / 30 fractions. Group B, aged 70 years or older, PS 0 or 1, and without any complications, or younger than 70 and PS 2 or with complications, received the concurrent carboplatin-paclitaxel chemoradiotherapy with 66 Gy / 33 fractions. Group C, aged 70 years or older and PS 2 or over, and with complications, received radiotherapy alone with 70 Gy / 35 fractions. Three-dimensional conformal radiation treatment planning including elective mediastinal nodal irradiation was performed. To evaluate treatment outcomes among the three groups, we estimated overall survival (OS), progression-free survival (PFS) and local progression-free survival (LPFS), and analyzed the differences in these indices statistically by means of EZR (ver1.32). We also evaluated the toxicity among these three groups with NCI-CTCAE ver.4.0. Result: The median of OS in Group A, B and C was 37.3 M, 40.4 M and 20.9 M, and that of PFS was 8.8 M, 17.9 M and 8.9 M, and that of LPFS was 25.9 M, 44.3 M and 22.8 M respectively. OS and LPFS were longer in Group A and B than C, and PFS was longer in B than C significantly (p＜0.05). There were no significant differences between Group A and B in any indices. In Group A, Radiation pneumonitis and esophagitis were
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